In reflecting on how to conclude this article, I had initially
planned on setting out the many uncertainties that remain in the law of medical
consent and decision-making. Ironically, however, late last week, the Supreme
Court of Canada released its decision in the case of Cuthbertson v. Rasouli, wherein it provided great
clarity and direction on the question of who holds the authority to make
end-of-life care treatment choices in Ontario.
On October 18, 2013, the Supreme Court of Canada dismissed an
appeal brought by doctors of Hassan Rasouli to unilaterally end his life-support
without the consent of his substitute decision-maker. In doing so, the Court
addressed two very interesting issues surrounding medical consent.
Substantively, the physicians of Mr. Rasouli contended that the
withdrawal of life support that does not provide any medical benefit to the
patient does not require consent as it does not constitute a “treatment” as
defined in the HCCA.
In disagreeing with this position, the Court clarified as follows:
·
“Treatment” and “medical benefit” are two distinct concepts.
Treatment is broadly defined as “anything that is done” for one of the enumerated
purposes (therapeutic, preventative, palliative, diagnostic and cosmetic) or
“other health-related purpose”. Medical benefit on the other hand is a
reflection of the standard of care that a physician is to provide a patient in
providing treatment.
·
“ ‘[T]reatment’ in the HCCA is broadly defined and therefore
should be understood as extending to withdrawal of life support…[which] aims at
the health-related purpose of preventing suffering and indignity at the end of
life, often entails physical interference with the patient’s body and is
closely associated with the provision of palliative care”
·
While the continuation of life support for a patient may place a
physician in an untenable ethical position, such tensions are inherent to
medical practice.
Procedurally, the
Court was called upon to assess whether the Court or the Consent and Capacity
Board (“Board”) was the appropriate forum for bringing challenges to consent
decisions. In upholding the statutory framework of the HCCA, the Court held that the Board was the proper place to make
determinations relating to consent to treatment for capable and incapable
patients:
“[The]
legal framework [of the HCCA], which
aims at protecting patients’ autonomy and medical interests, has been used to
resolve end-of-life disputes in Ontario for 17 years. Access to this
established regime should not be closed off, casting these matters back into
the courts.
“The HCCA does
not neglect the role of health practitioners in the treatment of incapable
patients. First, where there is a prior wish by the patient, the
attending physician may ask the Board to find that the wish is not applicable
to the patient’s current circumstances (s. 35), or to permit a departure from
the wish because the likely result of treatment has significantly improved
since the wish was made: s. 36. Second, if the physician feels that a
substitute decision-maker has not complied with the HCCA’s
rules for giving or refusing consent to treatment, he may challenge the consent
decision by application to the Board: s. 37. Such a challenge will
generally focus on medical considerations within the s. 21(2) best
interests analysis. The physician’s views of what will medically benefit
the patient are obviously critical to the Board’s determination of the patient’s
best interests. However, the HCCA gives the Board final
responsibility to decide disputes over consent to treatment for incapable
patients, based on an objective assessment of whether the substitute
decision-maker complied with the requirements of the HCCA.”
[Para 27]
This decision
reflects the great respect the Court gives to the principles of autonomy and
self-determination. In essence, it goes to empower substitute decision-makers,
including Attorneys for Care, to exercise the authority conferred upon them.
No comments:
Post a Comment